Contributions of a regional approach to document hematologic disease in Mexico: a 10-year experience in an open population

References

• Ferlay J, Soerjomataram II, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi: 10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Siegel R, Miller K, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi: 10.1016/j.ejca.2012.12.027
   PubMed Web of Science ®Google Scholar
• Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615–624. doi: 10.1182/blood-2013-06-508325
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, Heredia-Salazar AC, Cantú-Rodríguez OG, et al. Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico. Oncologist. 2015;20(4):386–392. doi: 10.1634/theoncologist.2014-0218
   PubMed Web of Science ®Google Scholar
• Bhakta N, Martiniuk ALC, Gupta S, et al. The cost effectiveness of treating paediatric cancer in low-income and middle-income countries: a case-study approach using acute lymphocytic leukaemia in Brazil and Burkitt lymphoma in Malawi. Arch Dis Child. 2013;98(2):155–160. doi: 10.1136/archdischild-2011-301419
   PubMed Web of Science ®Google Scholar
• Borja-Aburto VH, Dávila-Torres J, Rascón-Pacheco RA, et al. Cancer mortality in the Mexican social security institute, 1989–2013. Salud Publica Mex. 2016;58(2):153–161. doi: 10.21149/spm.v58i2.7784
   PubMed Web of Science ®Google Scholar
• Santoyo-Sanchez A, Olarte-carrillo I, Collazo-jaloma J, et al. The age and sex frequencies of patients with leukemia seen in two reference centers in the metropolitan area of Mexico City. 2016;152(2):186–189.
   Google Scholar
• INEGI. Encuesta Intercensal [Internet]. Encuesta Intercesal. 2015. Available from: http://www.inegi.org.mx/est/contenidos/Proyectos/encuestas/hogares/especiales/ei2015/.
   Google Scholar
• National Cancer I. SEER Stat Facts Sheets Cancer 2016: NCI Division of Cancer Control and Population Sciences [Internet]. 2016. Available from: https://seer.cancer.gov/statfacts/.
   Google Scholar
• Cancer Research UK. Acute lymphoblastic leukaemia (ALL) statistics London [Internet]. 2014. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-all.
   Google Scholar
• Ducasse K, Fernández JP, Salgado C, et al. Caracterización de los episodios de neutropenia febril en niños con leucemia mieloide aguda y leucemia linfoblástica aguda. Rev Chil infectología. 2014;31(3):333–338. doi: 10.4067/S0716-10182014000300013
   PubMedGoogle Scholar
• Demanelis K, Sriplung H, Meza R, et al. Differences in childhood leukemia incidence and survival between Southern Thailand and the United States: A population-based analysis. Pediatr Blood Cancer. 2015;62(10):1790–1798. doi: 10.1002/pbc.25571
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, Jiménez-Castillo RA, Herrera-Garza JL, et al. Survival rates of adults with acute lymphoblastic leukemia in a low-income population: a decade of experience at a single institution in Mexico. Clin Lymphoma Myeloma Leuk. 2017;17(1):60–68. doi: 10.1016/j.clml.2016.08.013
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, López-Razo ON, García-Arellano G, et al. Results of treating childhood acute lymphoblastic leukemia in a low-middle income country: 10 year experience in northeast mexico. Arch Med Res. 2016;47(8):668–676. doi: 10.1016/j.arcmed.2017.01.004
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, Jiménez-Castillo RA, Pinzón-Uresti MA, et al. Real-world outcomes of treatment for acute lymphoblastic leukemia during adolescence in a financially restricted environment: results at a single center in Latin America. Pediatr Blood Cancer. 2017;64(7):1–8. doi: 10.1002/pbc.26396
   Web of Science ®Google Scholar
• Jaime-Pérez JC, Pinzón-Uresti MA, Jiménez-Castillo RA, et al. Relapse of childhood acute lymphoblastic leukemia and outcomes at a reference center in Latin America: organomegaly at diagnosis is a significant clinical predictor. Hematology. 2018;23(1):1–9. doi: 10.1080/10245332.2017.1333294
   PubMed Web of Science ®Google Scholar
• Gómez-Almaguer D, Marcos-Ramírez ER, Montaño-Figueroa EH, et al. Acute leukemia characteristics are different around the world: the Mexican perspective. Clin Lymphoma Myeloma Leuk. 2017;17(1):46–51. doi: 10.1016/j.clml.2016.09.003
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788–2801. doi: 10.1002/cncr.20668
   PubMed Web of Science ®Google Scholar
• Arteaga-Ortiz L, Buitrón-Santiago N, Rosas-López A, et al. Experiencia del INCMNSZ en pacientes adultos con leucemia linfoide aguda. Cohorte 2003–2007 con esquemas de tratamiento Hiper-CVAD y Protocolo 0195. Rev Investig Clin. 2008;60(6):459–469.
   PubMedGoogle Scholar
• Jaime-Pérez JC, Fernández LT, Jiménez-Castillo RA, et al. Age acts as an adverse independent variable for survival in acute lymphoblastic leukemia: data from a cohort in northeast Mexico. Clin Lymphoma Myeloma Leuk. 2017;17(9):590–594. doi: 10.1016/j.clml.2017.06.016
   PubMed Web of Science ®Google Scholar
• World Health Organization. The global prevalence of anaemia in 2011. WHO Rep [Internet]. 2011:48. Available from: http://apps.who.int/iris/bitstream/10665/177094/1/9789241564960_eng.pdf?ua = 1.
   Google Scholar
• Gutierrez J, Rivera-Dommarco J, Shamah-Levy T, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Salud Publica Mex. 2012;1:1–196.
   Google Scholar
• López-García YK, Colunga-Pedraza PR, Tarín-Arzaga L, et al. Iron deficiency anemia referral to the hematologist. Real-world data from Mexico: the need for targeted teaching in primary care. Hematology. 2018;44:1–6.
   Google Scholar
• Candelaria M. Advances in the diagnosis and control of lymphomas. Salud Publica Mex. 2016;58(2):296–301. doi: 10.21149/spm.v58i2.7800
   PubMed Web of Science ®Google Scholar
• Freire SM, Calderón AM, Proaño GD, et al. Estudio Descriptivo : Características Clínicas. Demográficas e Histopatológicas de Pacientes con Diagnóstico de Linfoma no Hodgkin. 2015;7(3):230–235.
   Google Scholar
• Naz E, Mirza T, Aziz S, et al. Frequency and clinicopathologic correlation of different types of Non Hodgkin’s lymphoma according to WHO classification. J Pak Med Assoc. 2011;61(3):260–263.
   PubMed Web of Science ®Google Scholar
• Cancer Research UK. Non-Hodgkin lymphoma (NHL) Key Stats [Internet]. CancerStats. 2014. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/non-hodgkin-lymphoma/.
   Google Scholar
• Marrett LD, Frood J, Nishri D, et al. Cancer incidence in young adults in Canada: preliminary results of a cancer surveillance project. Chronic Dis Can. 2002;23(2):58–64.
   PubMedGoogle Scholar
• Jaime-Perez JC, Gamboa-Alonso CM, Vazquez-Mellado de Larracoechea A, et al. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma. Arch Med Res. 2015;46(6):454–461. doi: 10.1016/j.arcmed.2015.07.004
   PubMed Web of Science ®Google Scholar
• Rendón-Macías ME, Valencia-Ramón EA, Fajardo-Gutiérrez A, et al. Childhood lymphoma incidence patterns by ICCC-3 subtype in Mexico City metropolitan area population insured by Instituto Mexicano del Seguro Social, 1996–2010. Cancer Causes Control. 2015;26(6):849–857. doi: 10.1007/s10552-015-0558-8
   PubMed Web of Science ®Google Scholar
• Kühne T, Imbach P, Bolton-Maggs PH, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358(9299):2122–2125. doi: 10.1016/S0140-6736(01)07219-1
   PubMed Web of Science ®Google Scholar
• Abrahamson PE, Hall SA, Feudjo-Tepie M, et al. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83(2):83–89. doi: 10.1111/j.1600-0609.2009.01247.x
   PubMed Web of Science ®Google Scholar
• García-Stivalet AL, Muñoz-Flores A, Montiel-Jarquín ÁJ, et al. Análisis de 200 casos clínicos de púrpura trombocitopénica idiopática. Rev Medica Ins Mex Seguro Soc. 2014;52(3):322–325.
   PubMedGoogle Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917. doi: 10.1002/ijc.25516
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, Gamboa-Alonso CM, Padilla-Medina JR, et al. High frequency of primary refractory disease and low progression-free survival rate of Hodgkin’s lymphoma: A decade of experience in a Latin American center. Rev Bras Hematol Hemoter. 2017;39(4):325–330. doi: 10.1016/j.bjhh.2017.08.001
   PubMedGoogle Scholar
• Bröckelmann PJ, Borchmann P, Engert A. Current and future immunotherapeutic approaches in Hodgkin lymphoma. Leuk Lymphoma. 2016;57(9):2014–2024. doi: 10.1080/10428194.2016.1185789
   PubMed Web of Science ®Google Scholar
• Konkay K, Paul T, Uppin S, et al. Hodgkin lymphoma: a clinicopathological and immunophenotypic study. Indian J Med Paediatr Oncol. 2016;37(1):59. doi: 10.4103/0971-5851.177038
   PubMed Web of Science ®Google Scholar
• Makita S, Maruyama D, Maeshima AM, et al. Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol. 2016;104(2):236–244. doi: 10.1007/s12185-016-2007-1
   PubMed Web of Science ®Google Scholar
• Guía de Práctica Clínica. Diagnóstico y tratamiento de la Leucemia Mieloide Aguda. México: Secretaria de Salud; 2010. p. 1–46.
   Google Scholar
• Ocias LF, Larsen TS, Vestergaard H, et al. Trends in hematological cancer in the elderly in Denmark, 1980–2012. Acta Oncol (Madr). 2016;55(1):98–107. doi: 10.3109/0284186X.2015.1115124
   Google Scholar
• Buitrón-Santiago N, Arteaga-Ortiz L, Rosas-López A, et al. Experiencia del INCMNSZ en pacientes adultos con leucemia mieloide aguda. Cohorte 2003–2008. Rev Investig Clin. 2010;62(2):100–108.
   PubMedGoogle Scholar
• Jaime-Pérez JC, Brito-Ramirez AS, Pinzon-Uresti MA, et al. Characteristics and clinical evolution of patients with acute myeloblastic leukemia in Northeast Mexico: An eight-year experience at a university hospital. Acta Haematol. 2014;132(2):144–151. doi: 10.1159/000356794
   PubMed Web of Science ®Google Scholar
• Bower H, Andersson TML, Bjorkholm M, et al. Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life. Blood Cancer J. 2016;6(e390):1–6.
   Google Scholar
• Jaime-Pérez JC, Padilla-Medina JR, Fernández LT, et al. Outcomes of adolescents and young adults with acute myeloid leukemia treated in a single Latin American center. Clin Lymphoma Myeloma Leuk. 2018;18(4):286–292. doi: 10.1016/j.clml.2018.02.002
   PubMed Web of Science ®Google Scholar
• Osorio S, Casado LF, Giraldo P, et al. Leucemia mieloide crónica en españa: sus características de presentación han cambiado. sección española del registro poblacional EUTOS. Rev Clin Esp. 2016;216(6):293–300. doi: 10.1016/j.rce.2016.03.001
   PubMedGoogle Scholar
• Brunner AM, Campigotto F, Sadrzadeh H, et al. Trends in all-cause mortality among patients with chronic myeloid leukemia: a surveillance, epidemiology, and end results database analysis. Cancer. 2013;119(14):2620–2629. doi: 10.1002/cncr.28106
   PubMed Web of Science ®Google Scholar
• Cancer Research UK. Cancer Research Chronic Myeloid Leukemia Statistics [Internet]. 2014. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cml.
   Google Scholar
• Cantu-Rodriguez OG, Sanchez-Cardenas M, Gutierrez-Aguirre CH, et al. Cultural factors related to adherence to imatinib in CML: a Mexican perspective. Hematology. 2015;20(2):72–76. doi: 10.1179/1607845414Y.0000000165
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. doi: 10.4065/78.1.21
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles GJ, Gómez-Rangel JD, Ruiz-Delgado GJ, et al. Multiple myeloma in Mexico: a 20-year experience at a single institution. Arch Med Res. 2004;35(2):163–167. doi: 10.1016/j.arcmed.2003.09.013
   PubMed Web of Science ®Google Scholar
• Cancer Research UK. Myeloma incidence statistics [Internet]. Cancer Research UK. 2014. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/myeloma/incidence/.
   Google Scholar
• Ruiz-Argüelles G, Cantu-Rodriguez O, Mercado-Diaz L, et al. Some chronic lymphoproliferative malignancies in Mexico are less frequent than in Caucasian population. Blood. 1996;88(10):3596.
   Web of Science ®Google Scholar
• Tarin-Arzaga L, Arredondo-Campos D, Martínez-Pacheco V, et al. Impact of the affordability of novel agents in patients with multiple myeloma: Real world data of current clinical practice in Mexico. Cancer. 2018;124(9):1946–1953. doi: 10.1002/cncr.31305
   PubMed Web of Science ®Google Scholar